OKUR Stock Forecast: OnKure Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for OnKure Therapeutics, Inc. is $15. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 52 of 100 as at 18 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores OnKure Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (85): The share price has been relatively steady.
Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
OKUR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OKUR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 11 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | Oppenheimer | Reiterates | Outperform | $30 → $14 |
| 20 July 2026 | HC Wainwright & Co. | Maintains | Buy | $27 → $21 |
| 16 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | $34 → $27 |
| 26 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Mar 2025 | Oppenheimer | Maintains | Outperform | — |
| 28 Jan 2025 | Jones Trading | Initiates | Buy | — |
| 5 Dec 2024 | Leerink Partners | Initiates | Outperform | — |
| 8 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Oct 2024 | HC Wainwright & Co. | Assumes | Buy | $40 |
| 10 Oct 2024 | Oppenheimer | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OKUR.
This page is one stock. Monday covers all of them.
OKUR appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
OKUR vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, OnKure Therapeutics, Inc. returned 0.0% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
OKUR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- —
Cheaper than 81% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −55.2%
- Return on assets
- −34.4%
- Dividend yield
- —
Higher than 20% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
OnKure Therapeutics, Inc. has a market value of $116.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$58.7M.
Diluted earnings per share, trailing twelve months: −$3.50.
Free cash flow in the twelve months to 30 June 2026: −$47.9M.
OnKure Therapeutics, Inc. employs 45 people.
Data provided by Twelve Data
OKUR and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at OKUR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own OnKure Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about OKUR
What is the OKUR stock price forecast for 2026-2027?
The median 12-month analyst price target for OnKure Therapeutics, Inc. is $15, with estimates ranging from $11 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OKUR stock a buy right now?
Of the 6 analysts covering OnKure Therapeutics, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OnKure Therapeutics, Inc. 52 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OKUR?
As at 18 Nov 2026, OnKure Therapeutics, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (85 of 100).
Will OKUR stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts is $15, and Ticker Nerd's factor model ranks OnKure Therapeutics, Inc. 52 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OKUR stock forecast for 2030?
No analyst covering OnKure Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OKUR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $21 over the next 12 months.
How has OKUR stock performed over the past year?
OnKure Therapeutics, Inc. returned +0.0% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does OnKure Therapeutics, Inc. do?
OnKure Therapeutics, Inc. Class A Common Stock represents ownership in OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancers with biologically validated targets. The company’s current work centers on small-molecule drug candidates designed through structure-based drug design, with emphasis on oncology programs that modulate the PI3Kα signaling pathway.
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc. Class A Common Stock represents ownership in OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancers with biologically validated targets. The company’s current work centers on small-molecule drug candidates designed through structure-based drug design, with emphasis on oncology programs that modulate the PI3Kα signaling pathway. Its pipeline includes lead assets such as OKI-219, which is being studied for solid tumors, including breast cancer, and other product candidates aimed at addressing cancer types underserved by existing therapies. OnKure Therapeutics operates in the biotechnology sector and concentrates on clinical research and drug development, making it part of the broader market for targeted cancer therapeutics. Based in Boulder, Colorado, the company is positioned as a specialized developer of precision oncology treatments within the life sciences industry.
CEO Dr. Nicholas A. Saccomano Ph.D. · 45 employees · United States · https://onkuretherapeutics.com